^
Association details:
| Biomarker: | HAVCR2 expression |
|---|---|
| Cancer: | Renal Cell Carcinoma |
| Drug: | Opdivo (nivolumab) (PD1 inhibitor) + Yervoy (ipilimumab) (CTLA4 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
TIM3 expression on tumor cells predicts response to anti-PD-1 therapy for renal cancer
Published date:
10/22/2020
Excerpt:
...renal cell carcinoma (RCC) patients treated...with nivolumab monotherapy…nivolumab plus ipilimumab…Responders had significantly higher rate of TIM3-positive tumor (100% versus 53.9%, p < 0.01) than non-responders….Patients with TIM3-positive tumor showed significantly longer overall survival (not reached median time versus 6.0 months, p < 0.01) and progression-free survival (18.9 versus 1.1 months, p < 0.01) than those with TIM3-negative tumor.
DOI:
10.1016/j.tranon.2020.100918
